NCT07535008 Dental Cleaning to Prevent Chronic Graft-Versus-Host Disease
| NCT ID | NCT07535008 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Fred Hutchinson Cancer Center |
| Condition | Chronic Graft Versus Host Disease |
| Study Type | INTERVENTIONAL |
| Enrollment | 45 participants |
| Start Date | 2026-06-15 |
| Primary Completion | 2028-04-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 45 participants in total. It began in 2026-06-15 with a primary completion date of 2028-04-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This clinical trial evaluates the feasibility and effectiveness of a post-transplant dental cleaning for the prevention of chronic graft versus host disease (GVHD) in patients undergoing an allogeneic hematopoietic cell transplant (HCT). HCT is the only curative treatment for some types of blood cancer. Unfortunately, this approach can lead to the development of GVHD, which is a disease caused when cells from a donated stem cell graft attack the normal tissue of the transplant patient. Some research has shown that the bacteria that is present in the dental plaque soon after transplant may affect the development of chronic GVHD. Dental cleanings prior to transplant are part of the normal standard of care for patients undergoing HCT. Adding an additional cleaning shortly after HCT may be effective for preventing the development of chronic GVHD.
Eligibility Criteria
Inclusion Criteria: * Age ≥ 18 years old * T-replete allogeneic hematopoietic cell transplantation for any indication. History of prior transplantation is allowed. Any conditioning regimen is allowed * One of the following HCT donor types: * 9/10 or 10/10 human leukocyte antigen (HLA)-matched unrelated donor * Cord blood * Willing to have an in-person 1-year long-term follow-up (LTFU) visit including an oral medicine at Fred Hutch (FH) * Ability to understand and sign a written informed consent document (or legal representative) Exclusion Criteria: * Edentulous state * Bone marrow as graft source * Use of post-transplantation cyclophosphamide (PTCy) or ruxolitinib as GVHD prophylaxis * Use of anti-thymocyte globulin (ATG) in conditioning
Contact & Investigator
Armin Rashidi, MD, PhD
PRINCIPAL INVESTIGATOR
Fred Hutch/University of Washington Cancer Consortium
Frequently Asked Questions
Who can join the NCT07535008 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Chronic Graft Versus Host Disease. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07535008 currently recruiting?
Yes, NCT07535008 is actively recruiting participants. Contact the research team at arashidi@fredhutch.org for enrollment information.
Where is the NCT07535008 trial being conducted?
This trial is being conducted at Seattle, United States.
Who is sponsoring the NCT07535008 clinical trial?
NCT07535008 is sponsored by Fred Hutchinson Cancer Center. The principal investigator is Armin Rashidi, MD, PhD at Fred Hutch/University of Washington Cancer Consortium. The trial plans to enroll 45 participants.